Get Permission Waghmare, Kawade, and Nair: Mycobacterium abscessus presenting as a lung mass


Introduction

Non-tuberculosis mycobacteria (NTM) refers to all the organisms in the genus Mycobacterium except tuberculosis and leprae. Mycobacterium abscessus is a type of rapidly growing NTM. It typically infects those with underlying lung disease. The mode of infection in humans is environmental exposure or undergoing medical or cosmetic procedures. The clinical presentation is indistinguishable from mycobacterium tuberculosis. Due to the high case burden of tuberculosis in India, clinicians rarely consider the diagnosis of NTM. They are often evaluated for tuberculosis and incorrectly treated with anti-tuberculosis treatment. This adds to the morbidity and mortality of the disease. Due to a lack of pathognomonic clinical or radiological features, laboratory diagnosis is the gold standard. A multidrug regime is recommended due to high incidences of drug resistance. The treatment duration is long and response rates are low. We present a case report of mycobacterium abscessus presenting as a lung mass.

Case Presentation

A 38-year-old man presented to the respiratory OPD with complaints of fever, chest pain, and cough. He had these symptoms for 4 months. The patient didn’t suffer from any chronic disease or co-morbidities. He didn’t undergo any clinical procedures. Complete blood count and biochemical investigations were normal. A Chest X-ray demonstrated left lower zone opacity (Figure 1). It was confirmed to be an alveolar opacity (without air bronchogram) in the posterior and lateral basal segment of the left lower lobe on computerized tomography of the thorax (Figure 2). The sputum cartridge-based nuclei amplification test for negative for tuberculosis. A bronchoscopy was done to collect bronchial wash for culture. Mycobacterium abscessus was isolated via matrix-assisted desorption isonization- time of flight mass spectrometry. The drug sensitivity testing was also performed and the sensitivity pattern is given in Table 1. A drug regime consisting of intravenous amikacin, oral linezolid, clarithromycin, and moxifloxacin was started. This regime was designed to follow the drug sensitivity pattern and patient preferences.The patient was reassessed after 1 month of treatment. The symptoms had resolved, and the X-ray opacity had cleared (Figure 3).

Figure 1

Chest X-ray withleft lower zone opacity

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/2202d35b-c109-450d-82a1-77ca9e8acbb2/image/26a594a0-834f-4e85-b16f-342c73ebd48f-u2-copy.png
Figure 2

An alveolar opacity in the posterior and lateral basal segment of the left lower lobe

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/2202d35b-c109-450d-82a1-77ca9e8acbb2/image/fd273f21-49bf-460a-b159-dfbec675cff9-u2-copy.png
Figure 3

Resolution of left lower zone opacity

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/729f1ef3-91c6-496a-a723-95f6cd57e6a5image3.jpeg
Table 1

Drug sensitivity pattern

Sensitive

Intermediate

Resistant

Ciprofloxacin

Doxycycline

Trimethoprim/ Sulfamethoxazole

Moxifloxacin

Imipenem

-

Amikacin

Minocycline

-

Clarithromycin

-

-

Linezolid

-

-

Tobramycin

-

-

Discussion

Mycobacterium abscesses is one of the common causes of non-tuberculosis mycobacteria infection encountered in India and the world. It is known to infect skin, soft tissue, and lung disease. M. Abscesses belong to the rapid grower subdivision of the Runyon classification. The risk factors for pulmonary infection are underlying bronchiectasis, cystic fibrosis and a history of tuberculosis. It can only colonize the airways of diseased lungs.1 Our patient never had tuberculosis or any structural lung disease. Certain professions like gardening and farming are predisposed to the infection due to its presence in the soil and water. Iatrogenic introduction of the bacilli has been observed after medical, dental, and cosmetic procedures. 2, 3 In our case, the patient was a carpenter and hadn’t undergone any such procedures.

The symptoms of the M. abscessus infection depend upon the involved system. Respiratory system involvement presents with symptoms of chronic cough, fever, and chest pain. Often the chronicity of the symptoms is due to the delay in the diagnosis. In our case, the patient had symptoms of cough and chest pain for 4 months. In a TB-endemic country like India, the diagnosis is often delayed due to considerable overlap between the symptomatology of the mycobacterium tuberculosis and abscessus. Chest radiography showed left lower zone opacity in our patient. It was confirmed to be an alveolar mass without an air bronchogram in the left lower lobe on computerized tomography of the thorax. M. Abscessus presents with tree-in-bud appearance (nodules), bronchiectasis, and cavitation. 4, 5 There is no zonal or lobar preponderance. Mediastinal lymphadenopathy is less common. NTM are known to present as lung masses. This type of presentation is commonly seen with mycobacterium avium complex. 6 Due to the non-specificity of the clinical features, microbiological confirmation remains the only method of diagnosis. Sputum, protected bronchoscopic brush sample, or bronchial wash are used to culture the organism in the lab. In accordance with the national tuberculosis elimination programme guidelines, the patient was offered a sputum cartridge-based nucleic acid amplification test. The result was negative for tuberculosis. To confirm the diagnosis, the patient underwent a bronchoscopy. M. Abscessus was isolated by Matrix-assisted desorption isonization- time of flight mass spectrometry from the bronchial wash.

The treatment of lung disease consists of medical management and surgery. M. Abscessus is known to be resistant to macrolide and aminoglycoside.7 Therefore, it is prudent to perform drug susceptibility testing before treatment. The British Thoracic Society (BTS) guideline recommends sensitivity testing for minimum clarithromycin, cefoxitin, and amikacin. Often antibiotic sensitivity reports aren’t a true representation of in-vivo activity. M abscessus has natural defences against antibiotics like the erm gene. Macrolide resistance is attributed to this gene. It becomes active on prolonged exposure (>14 days) to macrolide antibiotics. 8

The antibiotics sensitivity pattern in our case is as per Table: 1. The drug regime is based on the clarithromycin sensitivity pattern. As per the BTS recommendations, intravenous medications should be administered for 4 weeks 9 followed by a long term oral regime. In our case, the patient decided against hospitalization or peripherally inserted central catheter insertion line (PICC) insertion. Therefore, the treatment regime was designed as per available the drug susceptibility pattern. The patient was prescribed an injection (intramuscular) of amikacin (thrice a week), and oral linezolid, clarithromycin, and moxifloxacin.

The challenges in medical management are compliance, adverse drug reactions, drug intolerance, long duration of treatment and drug resistance. Myelosuppression and ototoxicity are serious side-effects. 10 A meta-analysis involving 303 patients observed a success rate of 45.6%. 11 After 4 weeks of treatment, there was symptomatic improvement and resolution of X-ray opacity. The treatment will be continued for 1 year beyond culture negativity.

Conclusion

Mycobacterium abscessus often eludes diagnosis due to its nondescript clinical and radiological features. It wasn’t suspected in this case due to a lack of predisposing factors and unusual radiomorphology. Given the high mortality, a high index of suspicious should be exercised and samples(sputum, bronchial wash or tissue samples) should be processed for non-tuberculous mycobacteria.12 The untoward effects of the drugs and protracted course of antibiotics merit regular follow-up.

Source of Funding

None.

Conflict of Interest

None.

References

1 

HFM Abdelaal ED Chan L Young SL Baldwin RN Coler Mycobacterium abscessus: It’s ComplexMicroorganisms2022107145410.3390/microorganisms10071454

2 

G Gardini N Gregori A Matteelli F Castelli Mycobacterial skin infectionCurr Opin Infect Dis20223527987

3 

CF Chen J Liu SS Wang YF Yao B Yu XP Hu Mycobacterium abscessus infection after facial injection of argireline: A case reportWorld J Clin Cases20219819962000

4 

D Han KS Lee WJ Koh CA Yi TS Kim OJ Kwon Radiographic and CT Findings of Nontuberculous Mycobacterial Pulmonary Infection Caused by Mycobacterium abscessusAJR Am J Roentgenol200318125137

5 

MJ Chung KS Lee WJ Koh JH Lee TS Kim OJ Kwon Thin-section CT findings of nontuberculous mycobacterial pulmonary diseases: comparison between Mycobacterium avium-intracellulare complex and Mycobacterium abscessus infectionJ Korean Med Sci200520577783

6 

S Martinez HP Mcadams CS Batchu The Many Faces of Pulmonary Nontuberculous Mycobacterial InfectionAJR Am J Roentgenol2007189117786

7 

R Nessar E Cambau J M Reyrat A Murray B Gicquel Mycobacterium abscessus: a new antibiotic nightmareJ Antimicrob Chemother20126748108

8 

DE Griffith BA Brown-Elliott JL Benwill RJJ Wallace Mycobacterium abscessus. "Pleased to meet you, hope you guess my name..."Ann Am Thorac Soc20151234369

9 

CS Haworth J Banks T Capstick AJ Fisher T Gorsuch IF Laurenson British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)BMJ Open Respir Res201741e00024210.1136/ bmjresp-2017-000242

10 

J Chen L Zhao Y Mao M Ye Q Guo Y Zhang Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary DiseaseFront Microbiol197710197710.3389/fmicb.2019.01977

11 

N Kwak M P Dalcolmo C L Daley G Eather R Gayoso N Hasegawa Mycobacterium abscessus pulmonary disease: individual patient data meta-analysisEur Respir J2019541180199110.1183/13993003.01991-2018

12 

BW Jhun SM Moon K Jeon OJ Kwon H Yoo KC Carriere Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up studyEur Respir J2020551190079810.1183/13993003.00798-2019



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 14-10-2024

Accepted : 17-12-2024


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/ 10.18231/j.ijirm.2024.031


Article Metrics






Article Access statistics

Viewed: 157

PDF Downloaded: 20